Americord Registry has launched its newest stem cell banking product, Placental Tissue 2.0™. Americord was one of the first family cord blood banks to store placental tissue and now offers this exciting product, which stores live amniotic membrane (AM), a first for the industry.
Americord Registry was founded in 2008 and is based in New York City. Americord Registry specializes in umbilical cord blood, cord tissue, and placenta stem cell banking. As a private bank, Americord collects, processes, and stores stem cells for future medical or therapeutic use by the family who saves them. Americord is registered with the FDA and operates in all 50 states of the USA. The company’s laboratory is CLIA Certified, accredited by the AABB and complies with all federal and state guidelines and applicable licenses.
Placental Tissue 2.0™ allows a family to store two types of valuable stem cells: mesenchymal stem cells (MSCs), and a variety of stem cell called amniotic epithelial cells (or AECs). The MSCs collected in this process are more densely-packed and, when paired with the AECs, provide a more efficient resource that opens up many new treatment opportunities.
“Americord is a proven leader in stem cell banking and we are proud to announce our newest innovation which will truly benefit our customers. Placental Tissue 2.0™ offers almost double the stem cell output, allowing immediate potential for surgical wound healing as well as many other uses.”
“We developed Placental Tissue 2.0™ because of the desire to offer a stem cell product that extended the benefits of regenerative medicine to the whole family – not just the newborn. Unlike cord blood, the stem cells in this product do not need an HLA match for safe, effective use, so any first- or second-degree relative can benefit from storage.” – Martin Smithmyer, CEO of Americord